Hangzhou Tigermed - Public Comps and Valuation Multiples

Hangzhou Tigermed Overview

About Hangzhou Tigermed

Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's offered services include bioanalytical, medical writing, biostatistical analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Founded

2004

HQ

Employees

10.2K+

Website

tigermed.net

Sectors

Contract Research & Manufacturing
Laboratory Services
BioTech

Financials

LTM Revenue $946M

LTM EBITDA $189M

EV

$6.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Hangzhou Tigermed Financials

As of September 2025, Hangzhou Tigermed reported last 12-month revenue of $946M and EBITDA of $189M.

In the same period, Hangzhou Tigermed generated $316M in LTM gross profit and $127M in net income.

See Hangzhou Tigermed valuation multiples based on analyst estimates

Hangzhou Tigermed P&L

In the most recent fiscal year, Hangzhou Tigermed reported revenue of $926M and EBITDA of $158M.

Hangzhou Tigermed expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Hangzhou Tigermed valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$946M	XXX	$926M	XXX	XXX	XXX
Gross Profit	$316M	XXX	$314M	XXX	XXX	XXX
Gross Margin	33%	XXX	34%	XXX	XXX	XXX
EBITDA	$189M	XXX	$158M	XXX	XXX	XXX
EBITDA Margin	20%	XXX	17%	XXX	XXX	XXX
EBIT	$145M	XXX	$150M	XXX	XXX	XXX
EBIT Margin	15%	XXX	16%	XXX	XXX	XXX
Net Profit	$127M	XXX	$56.8M	XXX	XXX	XXX
Net Margin	13%	XXX	6%	XXX	XXX	XXX
Net Debt	XXX	XXX	$25.3M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Hangzhou Tigermed including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $946M. EBITDA for the last twelve months was $189M. In the most recent fiscal year, Hangzhou Tigermed achieved $926M in revenue and $158M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$946M	Analyst estimates available to subscribers	$926M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$316M	Analyst estimates available to subscribers	$314M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	33.4% gross margin	Analyst estimates available to subscribers	34.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$189M	Analyst estimates available to subscribers	$158M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	20.0% EBITDA margin	Analyst estimates available to subscribers	17.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$145M	Analyst estimates available to subscribers	$150M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	15.3% EBIT margin	Analyst estimates available to subscribers	16.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$127M	Analyst estimates available to subscribers	$56.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	13.4% net profit margin	Analyst estimates available to subscribers	6.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$25.3M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Hangzhou Tigermed

This financial data table provides comprehensive performance metrics for Hangzhou Tigermed, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Hangzhou Tigermed generated $946M in revenue over the last twelve months.
The company achieved $189M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $316M.
Net income over the last twelve months reached $127M.

Fiscal Year Performance

In the most recent fiscal year, Hangzhou Tigermed reported $926M in total revenue.
Fiscal year EBITDA was $158M.
The company maintained a gross profit margin of 34.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 17.1%.
Net profit margin reached 6.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Hangzhou Tigermed. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Hangzhou Tigermed Stock Performance

Hangzhou Tigermed has current market cap of CNY 44.3B (or $6.2B), and EV of CNY 45.1B (or $6.3B).

Market Cap Evolution

Hangzhou Tigermed Stock Data

As of October 17, 2025, Hangzhou Tigermed's stock price is CNY 51 (or $7).

See Hangzhou Tigermed trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$6.3B	$6.2B	XXX	XXX	XXX	XXX	$0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Hangzhou Tigermed Valuation Multiples

Hangzhou Tigermed's trades at 6.8x EV/Revenue multiple, and 39.9x EV/EBITDA.

See valuation multiples for Hangzhou Tigermed and 15K+ public comps

Hangzhou Tigermed Financial Valuation Multiples

As of October 17, 2025, Hangzhou Tigermed has market cap of $6.2B and EV of $6.3B.

Equity research analysts estimate Hangzhou Tigermed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Hangzhou Tigermed has a P/E ratio of 48.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$6.2B	XXX	$6.2B	XXX	XXX	XXX
EV (current)	$6.3B	XXX	$6.3B	XXX	XXX	XXX
EV/Revenue	6.7x	XXX	6.8x	XXX	XXX	XXX
EV/EBITDA	33.5x	XXX	39.9x	XXX	XXX	XXX
EV/EBIT	43.7x	XXX	42.2x	XXX	XXX	XXX
EV/Gross Profit	20.0x	XXX	n/a	XXX	XXX	XXX
P/E	48.9x	XXX	109.4x	XXX	XXX	XXX
EV/FCF	65.0x	XXX	60.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hangzhou Tigermed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Hangzhou Tigermed Margins & Growth Rates

Hangzhou Tigermed's last 12 month revenue growth is 9%

Hangzhou Tigermed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $16K for the same period.

Hangzhou Tigermed's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Hangzhou Tigermed's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Hangzhou Tigermed and other 15K+ public comps

Hangzhou Tigermed Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	9%	XXX	7%	XXX	XXX	XXX
EBITDA Margin	20%	XXX	17%	XXX	XXX	XXX
EBITDA Growth	21%	XXX	-31%	XXX	XXX	XXX
Rule of 40	49%	XXX	27%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	44%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$16K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	18%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial